RLV.V - Relevium Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0400
0.0000 (0.00%)
At close: 3:42PM EDT
Stock chart is not supported by your current browser
Previous Close0.0400
Open0.0400
Bid0.0400 x 0
Ask0.0450 x 0
Day's Range0.0350 - 0.0400
52 Week Range0.0100 - 0.1050
Volume719,813
Avg. Volume1,572,812
Market Cap7.954M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateMar. 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Relevium Provides Regulatory Update on Previously Announced Initiatives and Transactions

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), as a requirement in order to obtain final regulatory approval for its private placement as announced on Monday May 25, 2020, is pleased to provide a full update on the developments and transactions announced over the last 12 months. Relevium, like many other companies related to cannabis, experienced a significant decrease in its market valuation, which was proportional to the average decrease in value of all cannabis companies trading on both the CSE and TSX.

  • GlobeNewswire

    Relevium Announces Delayed Filing of Interim Disclosure Documents Pursuant to Temporary Relief Granted by Regulators due to COVID-19

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), today announced that it will be delaying the filing and delivery of certain of its continuous disclosure documents, in accordance with Decision No 2020-PDG-0023 of the Autorité des marchés financiers (Québec) (the “Exemption”),which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posed by the COVID-19 pandemic. The Company is relying on the Exemption by delaying the filing of its quarterly financial statements and related management discussion and analysis for the period ended March 31, 2020 required pursuant to National Instrument 51-102 Continuous Disclosure Obligations and the filing of the related certifications(collectively, the "Required Filings") and compliance with the delivery requirements of applicable securities laws relating to the Required Filings.

  • GlobeNewswire

    Relevium Announces $1.8M Private Placement and Closing

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce today a private placement offering of up to 58,000,000 units (the “Units”) of the Company at a price of $0.035 per Unit (the “Offering”), with each Unit consisting of one share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one common share of the Company at a strike price of $0.05 for a period of two years from the date of issuance. The Warrants are subject to an acceleration feature if the volume weighted average price of the common shares  trades at or above $0.075 on the TSX Venture Exchange (“TSXV”) for a period of 7 consecutive days starting from four months and a day from closing.

  • GlobeNewswire

    Relevium Expands CleanCare™ Hand Sanitizer Formats and Supply Capabilities; Company Targets Retirement Homes and Community Centers

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that its expanding its CleanCare™ hand sanitizing line to include two new retail formats as well as one new institutional format, the later targeting critical needs of retirement homes and community centers across Canada and the US. Relevium, through its integrated supply chain is successfully expanding production capabilities for CleanCare™ hand sanitizers to over 100,000 units per week. Bioganix® CleanCare™ hand sanitizer formulation kills 99.9% of germs and bacteria and is now available in 8 oz, 16 oz and 1-gallon formats.

  • GlobeNewswire

    Relevium to Present at Mi3 Online Investor Webinar

    Relevium Technologies Inc. (TSX.V:“RLV”, OTC:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company will be presenting at the Mi3 Investor and Broker Video Conference this Friday April 24th at 12:00PM Eastern Time. Aurelio Useche, CEO will discuss the “new normal” in terms of social interactions, in particular as we prepare to resume economic activities. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  • GlobeNewswire

    Relevium Reports $250,000 in Pre-Sales for Bioganix® CleanCare Hand Sanitizers in First 6 Days

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that its new line of Bioganix® CleanCare hand sanitizers has been met with very strong pre-sales demand of approximately one quarter of a million dollars since the product was made available on April 9, 2020. Last week, on April 9, 2020, the Company announced it had lunched its pre-order platform for its 8oz format of CleanCare of hand sanitizers on a pre-order first-come, first-served basis, making the product available, making the new product available in Canada and US. “We are very please with the initial reception of our Bioganix® CleanCare hand sanitizers, at a time when a new standard for social interactions and personal care is in development,” stated Aurelio Useche, CEO of Relevium.

  • GlobeNewswire

    RELEVIUM TO LAUNCH PHOTOCATALYTIC UV AIR PURIFICATION SYSTEM FOR BIOGANIX® CLEANCARE LINE

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today it has partnered with Montreal based air purification leaders to launch a new line of residential and office air purification systems. “There is now growing concern that the current and future viral infections could be transmitted via airborne particles and we expect that over the longer-term consumers will become more conscious about in-home prevention” stated Aurelio Useche, CEO of Relevium. The product will be available both, in Canada and in the United States through the Company’s native website www.bioganix.com.

  • GlobeNewswire

    RELEVIUM LAUNCHES PRE-ORDER OF BIOGANIX® CLEANCARE HAND SANITIZERS IN CANADA AND USA

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company has launched its newly launched Bioganix® CleanCare hand sanitizer product on pre-order to consumers in the Canadian market and the US. The Company will begin accepting pre-orders for the company’s new hand sanitizer products and will be shipped out to Canadian customers on a first-come first-served basis.

  • GlobeNewswire

    RELEVIUM SECURES NPN NUMBER WITH MANUFACTURING PARTNER AND IS READY TO MARKET BIOGANIX® CLEANCARE HAND SANITIZERS IN CANADA

    Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has secured the natural product number (“NPN”) for the Canadian market and is ready to launch the product for Canadian customers. Relevium is leveraging product formulation and manufacturing expertise of its integrated supply chain in Montreal to commercialize the newly announced Bioganix® CleanCare hand sanitizers that effectively kills 99.9% of germs and bacteria. The Company, through its local manufacturing partner, has secured Health Canada Natural Product Number (“NPN number”) and will begin accepting pre-sale orders on a first-come, first-served basis.

  • GlobeNewswire

    Relevium Launches Pre-Order of Bioganix® Cleancare Hand Sanitizers

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that a pre-order platform where customers can purchase in advance and reserve its new line of Cleancare hand sanitizers by Bioganix ®. The Company will begin accepting pre-orders for the company’s new Cleancare hand sanitizer products and will be shipped out to customers on a first come first serve basis.

  • GlobeNewswire

    RELEVIUM TO COMMERCIALIZE BIOGANIX® CLEANCARE HAND SANITIZERS

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today it has sourced and will begin commercializing a line of Bioganix® hand sanitizers. Relevium is leveraging its strong network of suppliers and formulators to manufacture and bring to market a line of hand sanitizers under the Bioganix ® Cleancare. The Company will have an initial format of 8oz (235ml) that will effectively kill 99.9% of germs and bacteria.

  • GlobeNewswire

    Relevium Announces the Passing of Dr. Tina Sampalis, Director and Scientific Officer

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is announces the passing of Dr. Tina Sampalis, Director and Scientific Officer of the Company. It is with heavy hearts and great sadness that we announce the passing of our colleague and friend Dr. Tina Sampalis MD, PhD. Tina passed peacefully on Sunday, March 1, 2020 after facing cancer with courage, resilience and tenacity.

  • GlobeNewswire

    Relevium Ships First Purchase Order Release of $130,000 to Middle East Customer

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the Company’s subsidiary, BGX E-Health LLC (“BGX”), has shipped a total of CAD $130,000 worth of generic formulations to its customer, Innova Health Care based in Saudi Arabia. This represents the first shipment of the initial CAD $1,000,000 purchase order the Company received, as mentioned in a press release dated October 30th 2019. CEO of Relevium Mr. Useche stated “This first shipment to our international customer presents a new milestone for the Company as it embarks on expanding with global partners around the world for generic formulations and nutraceuticals.”

  • GlobeNewswire

    Relevium Reports Improved Financial Results for Second Quarter of Fiscal 2020  

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal year ending June 30, 2020. The Company reported increased revenues for the reporting period.

  • GlobeNewswire

    Relevium Announces Update Call for Shareholders

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce a shareholder information video-conference call to provide an update on the current business and ongoing developments disclosed to the market. The CEO video-conference call will take this Friday February 7 at 12:00PM (Montreal or Eastern Time).

  • GlobeNewswire

    Relevium Provides Update on Newscope Transacion

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an update on the proposed transaction with Newscope Capital. As announced in a letter from the CEO issued on December 19, 2019, one of the Company’s main focus for 2020 is the crystallization of the value of the existing business units. On October 29, 2019, the Company announced it had executed an LOI with Newscope Capital to unlock the value of its nutraceutical business.

  • GlobeNewswire

    Relevium’s CEO Provides an Open Shareholder Letter for 2020

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an open letter to its shareholders from the company’s Chief Executive Officer, Aurelio Useche. As the year comes to a close and we take a look back at the Canadian capital markets in 2019 we see a new valuation model emerging and renewed investor diligence.

  • GlobeNewswire

    Relevium Launches LeefyLyfe™ Organic Hemp Products in the US

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of LeefyLyfeTM Organics, a comprehensive line of organic health and wellness products formulated with broad spectrum organically sourced Scandinavian hemp. The carefully crafted premium line of organic hemp extracts are sourced from slow-grown hemp and extracted with CO2 and formulated with MCT oil and rich flavonoids to enhance overall well-being. The Company has launched a 1000Mg Organic Hemp Oil Drops with Citrus flavonoids and a 1000Mg Organic Hemp Gummy Bears with Wild Berry flavonoids, both part of an initial series of eight (8) products planned to be released over the next six months.

  • GlobeNewswire

    Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract manufacturing company through its wholly owned subsidiary BGX e-Health LLC. The transaction is subject to customary due diligence and the parties have agreed to keep the vendors information confidential until such a time when the definitive agreement is executed. The target of the transaction is a Montreal based Biopharma company that manufactures for private label, white label and for its own brands of over the counter health products sold in Canada and the US.

  • GlobeNewswire

    Relevium Technologies Appoints Mark Billings as Chief Financial Officer

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities. Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business.

  • GlobeNewswire

    Relevium’s Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary, BGX E-Health LLC (“BGX”), has received a purchase order to supply Innova Health Care of Saudi Arabia with generic formulations totaling over CAD$1 Million. The Company has partnered with Montreal-based contract manufacturer BioV Pharma Inc., to fulfill the contract, which will be supplied in two shipments over the next six (6) months The first shipment, which totals approximately CAD$450,000 and is scheduled to be delivered before of the end of this year and the balance of the order is expected to be delivered during the first quarter of 2020.

  • GlobeNewswire

    Relevium Enters Into LOI to Unlock Value of Wholly Owned Subsidiary BGX E-Health LLC and Announces Conference Call With CEO

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce On October 25, 2019, the Company received a letter of intent (the “LOI”) to roll its interest in its wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”), a BC based privately held company seeking to become an aggregator in the wellness space, including CBD and hemp space. Under the preliminary terms of the LOI, Relevium with is expected to receive 20 Million shares of Newscope at $0.50 per share, representing approximately 86% of the resulting issuer.

  • GlobeNewswire

    Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones. Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.

  • GlobeNewswire

    Relevium Enters Into Manufacturing Agreement With Bio V Pharma and Registers 400 NPN Numbers With Health Canada  

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that it has registered four hundred (400) Natural Product Numbers (NPNs) with Health Canada through its main brand, Bioganix®, and entered into a manufacturing agreement with Bio V Pharma Inc. (“Bio V Pharma”), to manufacture, label and package Bioganix® products. Bio V Pharma is a Quebec-based, full-service manufacturer of pharmaceutical and nutraceutical products including vitamins, botanical products, food and veterinary supplements and specializes in capsules, tablets, liquids and semi-solids delivered in a variety of packaging formats. The registration of the NPN numbers allows Bioganix® to enter the Canadian market with 400 Health Canada approved products.

  • GlobeNewswire

    Relevium Announces Intention to Spin-Out Pediatric Cannabis Subsidiary Biocannabix

    Management, the board of directors and its advisors are pleased to announce the Company’s intention to create additional value for its shareholders through a potential spin-off of its medical cannabis business, thus creating an independent, publicly-traded and vertically-integrated biopharma business focused on paediatric endomedicine with expected dividends for shareholders. CPG (Consumer Packaged Goods): Through its US based business, BGX E-Health LLC, the Company generates revenues from direct-to-consumer sales of health and wellness products through a portfolio of trusted brands. Paediatric Biopharma: Through its Canadian based business, Biocannabix, the Company is highly focused on the development of paediatric endomedical (cannabinoid) formulations with a strong operational footprint in Canada (sales, import/export and research), Colombia (cultivation, extraction and clinical development) and Germany (Licensing and Distribution).